Calton & Associates, Inc. Travere Therapeutics, Inc. Transaction History

Calton & Associates, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 12, 2022	SELL	$23.61 - $30.6 $226,844 - $294,004	-9,608 Closed	0 $0
Q4 2021 Jan 13, 2022	SELL	$24.34 - $31.17 $4,089 - $5,236	-168 Reduced 1.72%	9,608 $298,000
Q3 2021 Nov 05, 2021	BUY	$12.98 - $25.03 $126,892 - $244,693	9,776 New	9,776 $237,000
Q2 2021 Aug 11, 2021	SELL	$14.11 - $26.4 $142,482 - $266,587	-10,098 Closed	0 $0
Q1 2021 May 03, 2021	BUY	$23.37 - $31.77 $303 - $413	13 Added 0.13%	10,098 $252,000
Q4 2020 Jan 25, 2021	BUY	$19.17 - $27.87 $193,329 - $281,068	10,085 New	10,085 $275,000

198

84.9M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Calton & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Calton & Associates, Inc. with notifications on news.